Published in Prostate on September 15, 2007
Bisphenol A promotes human prostate stem-progenitor cell self-renewal and increases in vivo carcinogenesis in human prostate epithelium. Endocrinology (2014) 1.81
Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate (2010) 1.78
Critical and distinct roles of p16 and telomerase in regulating the proliferative life span of normal human prostate epithelial progenitor cells. J Biol Chem (2008) 1.23
Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells. Am J Physiol Renal Physiol (2008) 1.16
Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies. Mol Med (2011) 1.13
Advances in complex multiparameter flow cytometry technology: Applications in stem cell research. Cytometry B Clin Cytom (2009) 1.10
Functional remodeling of benign human prostatic tissues in vivo by spontaneously immortalized progenitor and intermediate cells. Stem Cells (2010) 1.09
Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res (2008) 1.08
ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate. Cell Cycle (2009) 1.01
Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol Cancer Ther (2010) 1.01
Cardiac side population cells: moving toward the center stage in cardiac regeneration. Circ Res (2012) 0.98
Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/β-catenin pathway. J Exp Clin Cancer Res (2011) 0.97
Human prostate side population cells demonstrate stem cell properties in recombination with urogenital sinus mesenchyme. PLoS One (2013) 0.97
Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells. Clin Cancer Res (2011) 0.97
Prostate cancer stem cells. Clin Genitourin Cancer (2012) 0.96
Identification, characterization, and biological relevance of prostate cancer stem cells from clinical specimens. Urol Oncol (2009) 0.94
Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies. Endocr Rev (2008) 0.92
Actions of estrogens and endocrine disrupting chemicals on human prostate stem/progenitor cells and prostate cancer risk. Mol Cell Endocrinol (2011) 0.90
Cancer stem cells and epithelial ovarian cancer. J Oncol (2011) 0.89
Isolation and applications of prostate side population cells based on dye cycle violet efflux. Curr Protoc Toxicol (2011) 0.89
Disruption of prostate epithelial differentiation pathways and prostate cancer development. Front Oncol (2013) 0.89
Insights into Chemoresistance of Prostate Cancer. Int J Biol Sci (2015) 0.86
Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling. PLoS One (2012) 0.83
Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells. Biochim Biophys Acta (2011) 0.81
Targeting prostate cancer stem cells for cancer therapy. Discov Med (2012) 0.80
Early human prostate adenocarcinomas harbor androgen-independent cancer cells. PLoS One (2013) 0.79
Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies. Anticancer Agents Med Chem (2010) 0.79
Dynamic modeling of genes controlling cancer stem cell proliferation. Front Genet (2012) 0.79
Prostate epithelial stem and progenitor cells. Am J Clin Exp Urol (2014) 0.79
Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference. Prostate (2011) 0.78
Expressions of ABCG2, CD133, and podoplanin in salivary adenoid cystic carcinoma. Biomed Res Int (2014) 0.77
A novel fixative for immunofluorescence staining of CD133-positive glioblastoma stem cells. J Neurosci Methods (2011) 0.77
Redox signaling in cardiac renewal. Antioxid Redox Signal (2014) 0.77
Gene Expression in Single Cells Isolated from the CWR-R1 Prostate Cancer Cell Line and Human Prostate Tissue Based on the Side Population Phenotype. Single Cell Biol (2016) 0.75
Regulatory mechanisms of microRNAs in lung cancer stem cells. Springerplus (2016) 0.75
Regulation of voltage-gated potassium channels attenuates resistance of side-population cells to gefitinib in the human lung cancer cell line NCI-H460. BMC Pharmacol Toxicol (2017) 0.75
Characteristics of primary side population cervical cancer cells. Oncol Lett (2017) 0.75
Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol (2013) 3.85
A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood (2004) 2.90
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol (2012) 2.31
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol (2012) 2.06
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials (2009) 1.81
Early prostate cancer--which treatment do men prefer and why? BJU Int (2010) 1.79
Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate (2002) 1.52
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials (2012) 1.48
Should centralized histopathological review in penile cancer be the global standard? BJU Int (2014) 1.39
CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer (2009) 1.21
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int (2008) 1.19
Novel method for the isolation and characterisation of the putative prostatic stem cell. Cytometry A (2003) 1.18
Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. Stem Cells Dev (2009) 1.17
Measurement of elastic properties of prostate cancer cells using AFM. Analyst (2008) 1.17
Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells. Am J Physiol Renal Physiol (2008) 1.16
Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol (2011) 1.10
Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. Eur Urol (2009) 1.06
Molecular mechanisms of metastasis in prostate cancer. Asian J Androl (2008) 1.06
The combined application of FTIR microspectroscopy and ToF-SIMS imaging in the study of prostate cancer. Faraday Discuss (2004) 1.04
The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK. BJU Int (2006) 1.03
Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. Eur Urol (2004) 1.01
Reflection contributions to the dispersion artefact in FTIR spectra of single biological cells. Analyst (2009) 0.96
Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy. J Lipid Res (2007) 0.96
FTIR microscopy of biological cells and tissue: data analysis using resonant Mie scattering (RMieS) EMSC algorithm. Analyst (2012) 0.95
Spectral discrimination of live prostate and bladder cancer cell lines using Raman optical tweezers. J Biomed Opt (2009) 0.93
AC133+ G0 cells from cord blood show a high incidence of long-term culture-initiating cells and a capacity for more than 100 million-fold amplification of colony-forming cells in vitro. Stem Cells (2004) 0.91
Imaging angiogenesis of genitourinary tumors. Nat Rev Urol (2010) 0.90
Discrimination of prostate cancer cells and non-malignant cells using secondary ion mass spectrometry. Analyst (2007) 0.88
Investigating FTIR based histopathology for the diagnosis of prostate cancer. J Biophotonics (2009) 0.88
FTIR microspectroscopy of selected rare diverse sub-variants of carcinoma of the urinary bladder. J Biophotonics (2012) 0.88
Assessing the challenges of Fourier transform infrared spectroscopic analysis of blood serum. J Biophotonics (2014) 0.87
Optical artefacts in transflection mode FTIR microspectroscopic images of single cells on a biological support: the effect of back-scattering into collection optics. Analyst (2007) 0.87
A correlation of FTIR spectra derived from prostate cancer biopsies with gleason grade and tumour stage. Eur Urol (2006) 0.87
A contemporary standard for morbidity and outcome after radical cystectomy. BJU Int (2009) 0.85
Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys (2005) 0.84
SR-FTIR spectroscopy of renal epithelial carcinoma side population cells displaying stem cell-like characteristics. Analyst (2010) 0.82
The influence of lipid metabolism on prostate cancer development and progression: is it time for a closer look? Eur Urol (2007) 0.82
Whole organ cross-section chemical imaging using label-free mega-mosaic FTIR microscopy. Analyst (2013) 0.81
Cd133: a marker of transit amplification rather than stem cell phenotype in the prostate? BJU Int (2008) 0.80
Impact of socioeconomic status on bladder cancer outcome. Curr Opin Urol (2005) 0.80
Copper modulates zinc metalloproteinase-dependent ectodomain shedding of key signaling and adhesion proteins and promotes the invasion of prostate cancer epithelial cells. Mol Cancer Res (2012) 0.77
Should all patients receive statins to reduce cancer risk after heart transplantation? Circulation (2012) 0.77
Discrimination of prostate cancer cells by reflection mode FTIR photoacoustic spectroscopy. Analyst (2007) 0.77
Classification of fixed urological cells using Raman tweezers. J Biophotonics (2009) 0.76
Late tissue effects following radiotherapy and neoadjuvant hormone therapy of the prostate measured with quantitative magnetic resonance imaging. Radiother Oncol (2008) 0.76
Editorial comment on: noninvasive detection of testicular carcinoma in situ in semen using OCT3/4. Eur Urol (2007) 0.75
Bisphosphonates in hormone-refractory prostate cancer: do we have a toxicity problem? Eur Urol (2008) 0.75
Chemotherapy in hormone refractory prostate cancer: where do we stand? Eur Urol (2004) 0.75
Coming up for air: follow-up and risk stratification after negative prostate cancer screening. Eur Urol (2012) 0.75
Clinical guidelines: should 5 alpha-reductase inhibitors be used for prostate disease? Nat Rev Urol (2009) 0.75
The molecular staging of prostate cancer. BJU Int (2004) 0.75
Integrating surgery with targeted therapies for renal cell carcinoma: maximizing benefits, minimizing risk. Eur Urol (2010) 0.75
Infrared spectral histopathology using haematoxylin and eosin (H&E) stained glass slides: a major step forward towards clinical translation. Analyst (2016) 0.75
Aetiology, diagnosis and management of urothelial tumours of the renal pelvis and ureter. BJU Int (2008) 0.75
Is population screening for prostate cancer good or bad? Eur Urol (2010) 0.75
Identification and evaluation of clinically significant prostate cancer: a step towards personalized diagnosis. Curr Opin Urol (2017) 0.75
Male adnexal tumour of probable Wolffian duct origin. Scand J Urol Nephrol (2005) 0.75
Should molecular technology replace urine cytology? BJU Int (2008) 0.75
The origin of the bone scan as a tumour marker in prostate cancer. Eur Urol (2006) 0.75
Male adnexal tumour of wolffian origin: the first report of metastatic disease. Scand J Urol Nephrol (2009) 0.75